Objective: To evaluate the application of micro-flow imaging(MFI) in the detection of particulate matters in biochemical protein drugs(urokinase for injection), and to investigate the status of particulate matters in urokinase samples for injection from various manufactures, and the differences of particulate matters after resolution with two different solvents, and find out the main origin of particulate matters. Methods: The urokinase for injection was re-dissolved in either sterilized water for injection or sterilized normal saline for injection respectively, and the particulate matters were analyzed by MFI. The MFI methodology was validated, comparing with light obscuration method. Results: For 5 μm and 15 μm particulate standard detected by MFI, the counting accuracy(deviations) of particle count were 11.6% and 8.5%, precision(RSDs) were 1.6% and 3.8%, the accuracy (deviations) were 2.5% and 0.8%, precision(RSDs) were 0.6% and 0.1%. In the results of determination of particulate matters detected by MFI with the particle size of 2-10 μm were mainly proteinaceous, and the partide size of more than 10 μm were mainly non-proteinaceous. The result of non-proteinaceous particulate matters detected by MFI was similar to light obscuration method. The particulate matters in urokinase for injection produced by different manufactures were quite different, and the particulate matters for manufacturer A was more. There was no significant difference in the results of particulate matters after dissolved with two different solvents for samples from manufacturer A and C, and significant difference for samples from manufacture B and D. Particulate matters were less for samples re-dissolved with sterilized normal saline. Conclusion: MFI was first applied to detect particulate matters in biochemical protein drugs (urokinase for injection). It provides new ideas for exploring the source of particulate matters in biochemical protein drugs. The results of particulate matters in individual manufactures were close to the limit, suggesting that the manufactures need to strengthen research and development to improve product quality control. And manufactures can analyze the main sources of particulate matters from endogenous and exogenous cause according to the result of 2-10 μm range and particle size more than 10 μm.Reconstitution with different two solvents affected the results of particulate matters for some samples, and particulate matters are less for samples dissolved with sterilized normal saline. But the cause of the above results need further study.
XU Ming-ming, YAN Cui-xia, ZHOU Qin, CHEN Gang, ZHENG Lu-xia, SHAO Hong
. Application of MFI in the detection of particulate matters in urokinase for injection[J]. Chinese Journal of Pharmaceutical Analysis, 2023
, 43(1)
: 29
-36
.
DOI: 10.16155/j.0254-1793.2023.01.04
[1] 胡著阳, 魏超娟, 耿卫锋. 尿激酶的质量研究[J].生物化工, 2019, 5(4):122
HU ZY, WEI CJ, GENG WF. Study on the quality of urokinase[J].Biol Chem Eng, 2019, 5(4):122
[2] 孙天霄, 王红梅, 徐长法. 高分子量和低分子量尿激酶的分离纯化及动力学性质研究[J].生物化学杂志, 1997, 13(3):344
SUN TX, WANG HM, XU CF. Study on the separation and purification of high and low molecular weight urokinase and its kinetic properties[J].Chin Biochem J, 1997, 13(3):344
[3] 李艳红. 尿激酶与3种输液配伍的不溶性微粒分析[J].求医问药, 2013, 11(1):565
LI YH. The analysis of insoluble particles in urokinase with three kinds of infusion[J].Seek Med Ask Med, 2013, 11(1):565
[4] 中华人民共和国药典2020年版. 二部[S].2020: 653
ChP 2020. Vol Ⅱ[S].2020: 653
[5] BP 2019. Vol Ⅱ[S].2019: 1219
[6] EP 10.0. Vol Ⅲ[S].2019: 4151
[7] JP ⅩⅦ[S].2016: 1747
[8] LEVIN I, ZIGMAN S, KOMLOSH A, et al. Development of flow imaging analysis for subvisible particle characterization in glatiramer acetate[J].J Pharm Sci, 2015, 104(2):3977
[9] AKHUNZADA ZS, HUBERT M, SAHIN E, et al. Separation, characterization and discrimination analysis of subvisible particles in biologics formulations [J].Curr Pharm Biotechnol, 2019, 20(3):1
[10] USP-NF. <787> Subvisible Particulate matter in Therapeutic Protein Injections[S].2020
[11] 郭莎, 武刚, 崔永霏, 等. 2种型号微粒成像分析仪测定微粒标准品及单抗样品的结果比对[J].药物分析杂志, 2021, 41(4):655
GUO S, WU G, CUI YF, et al. Comparison of two models of micro-flow digital imaging instruments in the measurement of particle standards and monoclonal antibodies[J].Chin J Pharm Anal, 2021, 41(4):655
[12] NARHI LO, SCHMIT J, BECHTOLD-PETERS K, et al. Classification of protein aggregates[J].J Pharm Sci, 2012, 101(2):493
[13] NARHI LO, CORVARI V, RIPPLE DC, et al. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: part 1, considerations and strategy [J].J Pharm Sci, 2015, 104(6):1899
[14] BRANARD JG, SINGH S, RANDOLPH TW, et al. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway[J].J Pharm Sci, 2011, 100(2):492
[15] SIMLER BR, GUO DH, DAHL JE, et al. Mechanistic complexity of subvisble particle formation: links to protein aggregation are highly specific[J].J Pharm Sci, 2012, 101(11):4140
[16] Food and Drug Administration(FDA). Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products[Z].2014